Manish B. Patel

Suggest Changes
  • Citations Per Year
Learn More
INTRODUCTION Despite a clinically relevant, statistically significant survival benefit with nab-paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer(More)
BACKGROUND We compared real-world treatment patterns, resource utilization, and cost of care for patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel + gemcitabine or(More)
INTRODUCTION Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or(More)
withHRof 0.55, 0.56, 0.43, 0.16 for age groups<45, 75-79, 80-84, and >85, respectively(P < 1x10). LC survivors with carcinoma, NOS or carcinoid had significantly reduced risks versus(More)
  • 1